Daily FNArena News - Small Caps

All | Australia | Book Reviews | Commodities | ESG Focus | FYI | International | Small Caps | Technicals | Treasure Chest

Latest Stories

Capitol Health’s first half results exceeded brokers’ expectations with higher margins thanks largely to stringent cost control

Mar 13 2024

Tim Boreham reports Neuren Pharmaceuticals has suffered from accusations from an activist shorter which others have debunked

Mar 11 2024


Dicker data shares fell -10% yesterday but it had nothing to do with the company’s AI-fuelled outlook

Mar 07 2024

Profit season brings out the best and worst in small caps, and sometimes both at once, reports The New Criterion’s Tim Boreham

Feb 29 2024


Previous Stories

Hansen Technologies: Focus On FY26

Feb 26 2024

A disappointing update on recently acquired powercloud does not ruin the investment case for Hansen Technologies, analysts say


Data#3 Guilty Of Miscommunication

Feb 19 2024

While Data3#’s earnings result confirmed its January trading update, the market was not impressed with how profit growth was achieved


Reckon’s New Lease Of Life

Feb 15 2024

Run-of-the-mill accounting software company Reckon may be set for a re-rating, brokers believe


Dr Boreham’s Crucible: Artrya

Feb 15 2024

Artificial intelligence and some valuable experiences should benefit heart device developer Artrya, Tim Boreham explains


Spotlight On ASX-Listed Cannabis Companies

Jan 31 2024

Some cannabis gems are sprouting in the ASX weed patch, but they are hard to find in the haze of hype, Tim Boreham, Editor, The New Criterion reports


Judo Answers The Critics

Jan 24 2024

In response to a broker’s negative assessment, Judo Capital has provided a surprise trading update that significantly exceeded expectations


Transformational Trial Results For Neuren Pharmaceuticals

Dec 20 2023

Brokers raise valuations for Neuren Pharmaceuticals following positive Phase 2 clinical trial results


Dr Boreham’s Crucible: Imugene

Dec 11 2023

Tim Boreham highlights the prospects for cancer treatment biotech Imugene


Luxury Cars Still Selling For Autosports

Nov 28 2023

Despite higher interest rates, Autosports Group is seeing no easing in demand for luxury cars, providing solid revenue growth guidance at its AGM


Dr Boreham’s Crucible: PYC Therapeutics

Nov 22 2023

Tim Boreham highlights how PYC Therapeutics’ gene therapy can address a plethora of genetic afflictions



Analyse The Market From A Different Angle